CoQ10/Ubiquinol

Key Research Papers and Clinical Trials

Research on CoQ10 and its reduced form ubiquinol has expanded across several areas, though many studies remain small-scale or preliminary.

Human Studies

Several completed clinical trials have investigated CoQ10/ubiquinol in different populations. A Phase 1 study (NCT03893864) examined bioavailability and exercise effects in older athletes, while another Phase 1 trial (NCT03020680) specifically compared absorption of ubiquinone versus ubiquinol in older adults. More clinically-focused research includes a Phase 2 trial investigating ubiquinol's potential role in post-cardiac arrest recovery (NCT02934555) and another Phase 2 study examining whether CoQ10 supplementation could reduce chemotherapy-related side effects in breast cancer patients (NCT06570811).

A Phase 2/3 trial (NCT04870502) explored ubiquinol supplementation for women with clomiphene citrate-resistant ovulation disorders, representing one of the larger-scale investigations.

Laboratory and Safety Research

Basic research has focused on understanding CoQ10's absorption and safety profile. A 2023 study in mice (PMID: 36936872) found that both ubiquinol and ubiquinone are absorbed by the small intestine largely in their original forms, providing insight into bioavailability mechanisms. Safety evaluation has included in vitro testing of a novel ubiquinol formulation (PMID: 39524701) published in 2024.

Interestingly, a 2026 population study from Northern Germany (PMID: 41897489) reported an association between higher CoQ10 redox states and increased mortality risk, though the study design and sample size are not detailed in the available evidence.

Veterinary Applications

Several small-scale veterinary studies have examined CoQ10 effects in animals. Research has included evaluation in male donkeys (PMID: 41777613), case studies of semen quality in dogs (PMID: 34011783), and effects on stallion reproductive parameters (PMID: 33349408). A bioavailability study in burn patients was also conducted (PMID: 35888737), though sample sizes and detailed methodologies are not provided in the available evidence.

Stability Concerns

One study highlighted potential stability issues with ubiquinol formulations (PMID: 34602873), which could have implications for supplement quality and efficacy.

Note: This synthesis is based on limited evidence details. Full study results, sample sizes, and methodological details would be needed for comprehensive evaluation. These findings should not be used for personal medical decisions without consulting healthcare providers.